Month: November 2011

Positive results from Genomic Health ’s ( GHDX ) QUASAR clinical validation study were recently published by the Journal of Clinical Oncology (JCO). The company has for quite some time been awaiting the publication of the study. […]

Tobacco companies heaved a sigh of relief as a federal judge blocked the rule that mandated tobacco warning labels on the cigarette packets. The images and texts or the health warnings, which were designed by the Food and Drug Administration (FDA), were considered to violate these companies’ right of free speech and have been blocked by U.S. […]

Yesterday, the board of Allstate Corporation ( ALL ) announced the approval of a new share repurchase program worth $1.0 billion. While the share buy back will be made through open market operations, it is scheduled to complete by March 31, 2013. Accordingly, the auto and home insurer of the US – Allstate plans to fund the share repurchases and another listed debt maturity next year through its debt capital […]

Novartis ( NVS ) recently announced that a late-stage trial evaluating its pipeline candidate, ACZ885, for the treatment of children with active systemic juvenile idiopathic arthritis (SJIA) met the two primary endpoints. The data revealed that within 28 weeks of treatment with ACZ885, 45% of the children were able to reduce their use of steroids. […]

We recently upgraded our recommendation on The Hain Celestial Group Inc. ( HAIN ) – which distributes, markets, and sells various natural and organic foods as well as personal care products – to Outperform with a price target of $37.00. […]

Leading medical devices maker C.R. Bard ’s ( BCR ) third-quarter 2011 adjusted earnings per share of $1.62 topped the Zacks Consensus Estimate of $1.60 and exceeded the year-ago earnings of $1.43. Profit (as reported) for the quarter rose 2% year over year to $130.1 million (or $1.46 a share) on higher revenues […]

Aura Gets CE Mark Brian Marckx, CFA Verisante ( V.VRS ) continues to deliver on key milestones and this morning announced that they have obtained CE Mark for approval to sell Aura in Europe. CE Marking also allows Verisante to market the device in Australia. The approval comes on the heels of Health Canada regulatory clearance which was granted in mid-October. […]

GOL Linhas A ( GOL ) will be reporting its third-quarter 2011 earnings on Thursday, November 10, 2011. The current Zacks Consensus Estimate for earnings per share (EPS) is a negative 23 cents, representing an annualized loss of 197.50%. With respect to earnings surprises over the trailing four quarters, GOL outperformed the Zacks Consensus Estimate in two quarters and underperformed in the rest […]